Drug Profile

Research programme: amphiphile CAR T cell therapy - Elicio Therapeutics

Latest Information Update: 26 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Elicio Therapeutics
Class Antineoplastics; Cancer vaccines; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Dendritic cell stimulants; Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Jun 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (before June 2023) (Elicio Therapeutics Pipeline, June 2023)
21 Sep 2020 Preclinical trials in Solid tumours in USA (Parenteral) (Elicio Therapeutics pipeline, September 2020)
04 Apr 2019 Early research in Solid tumours in USA (Parenteral) (Elicio pipeline, April 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com